Company Analysis
Sign in

Ardelyx, Inc. (ARDX)

Nasdaq: ARDX · Pharmaceutical Preparations · Fremont, CA · filing with the SEC since 2008
Full chart Alerts Compare
Grade5.9
◀ Past 5.2● Present 6.6▶ Future 5.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

39 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ardelyx, Inc.’s names, not what it holds today.

Patents granted
39
39 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 3 in 2024 and 4 in 2023
Applications published
64
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Organic fine chemistry5
Optics1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Ardelyx, Inc. its own name
US, as the owner printed on each patent
39 granted
38 published
Ardelyx, Inc. its own name
named as the applicant on its applications, in US
0 granted
26 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 22, 202512,281,103Compounds useful for treating gastrointestinal tract disordersOrganic fine chemistryArdelyx, Inc.
Jan 28, 202512,209,088Hormone receptor modulators for treating metabolic conditions and disordersOrganic fine chemistryArdelyx, Inc.
Sep 10, 202412,084,472Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonistsOrganic fine chemistryArdelyx, Inc.
Jun 25, 202412,016,856Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersPharmaceuticalsArdelyx, Inc.
Jan 2, 202411,858,959Glycyrrhetinic acid derivatives for use in treating hyperkalemiaPharmaceuticalsArdelyx, Inc.
Nov 14, 202311,813,304Compounds and methods for inhibiting phosphate transportPharmaceuticalsArdelyx, Inc.
Sep 26, 202311,768,319Glycyrrhetinic acid derivatives for treating hyperkalemiaOpticsArdelyx, Inc.
Sep 12, 202311,753,410Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disordersOrganic fine chemistryArdelyx, Inc.
Aug 8, 202311,718,619Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activatorsPharmaceuticalsArdelyx, Inc.
May 3, 202211,318,129Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersPharmaceuticalsArdelyx, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388615SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTSOrganic fine chemistryArdelyx, Inc.
Dec 4, 20252025/0367188COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERSPharmaceuticalsArdelyx, Inc.
Aug 21, 20252025/0263401COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERSOrganic fine chemistryArdelyx, Inc.
Aug 14, 20252025/0255860ORAL FORMULATION OF A THERAPEUTIC COMPOUNDPharmaceuticalsArdelyx, Inc.
Apr 10, 20252025/0115608HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERSOrganic fine chemistryArdelyx, Inc.
Feb 27, 20252025/0067907COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIAOpticsArdelyx, Inc.
Feb 27, 20252025/0066410SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTSOrganic fine chemistryArdelyx, Inc.
Nov 7, 20242024/0366590COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERSPharmaceuticalsArdelyx, Inc.
Nov 7, 20242024/0366589NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORTPharmaceuticalsArdelyx, Inc.
Oct 3, 20242024/0325487COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORTPharmaceuticalsArdelyx, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 7 · Organic fine chemistry 5 · Optics 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ARDX · research, not advice